Publications by authors named "Michael Stecher"

Claim this Profile
S
Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
Harshabad Singh, Ashley Kang, Lisa Bloudek, Ling-I Hsu, Maria Corinna Palanca-Wessels, Michael Stecher

JNCI Cancer Spectr· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
John H Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F Siadak

J Natl Compr Canc Netw· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Michael Stecher

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.
Razelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, Mark Saunders, Qian Wu, Michael Stecher

Oncoimmunology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
Theodora Kanni, Maria Argyropoulou, Themistoklis Spyridopoulos, Aikaterini Pistiki, Michael Stecher

J Invest Dermatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.
Tamas Hickish, Thierry Andre, Lucjan Wyrwicz, Mark Saunders, Tomasz Sarosiek, Michael Stecher

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization.
Hosam El Sayed, Richard Kerensky, Michael Stecher, Prasant Mohanty, Mark Davies

J Vasc Surg· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Reply.
Kyle M Coleman, Johann E Gudjonsson, Michael Stecher

JAMA Dermatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
David S Hong, Filip Janku, Aung Naing, Gerald S Falchook, Sarina Piha-Paul, Michael Stecher

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity.
Daniel Carrasco, Michael Stecher, Gigi Claire Lefebvre, Alan C Logan, Ronald Moy

J Drugs Dermatol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis.
Kyle M Coleman, Johann E Gudjonsson, Michael Stecher

JAMA Dermatol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
David S Hong, David Hui, Eduardo Bruera, Filip Janku, Aung Naing, Michael Stecher

Lancet Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis